Eventide Asset Management’s Cytokinetics CYTK Stock Holding History

Eventide Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.1M	Buy	564,398 +85,300	+18%	+$6.12M	0.64%	53
2026 Q1	$31.6M	Sell	479,098 -513	-0.1%	-$32.6K	0.52%	66
2025 Q4	$30.5M	Buy	479,611 +309,503	+182%	+$19.3M	0.48%	77
2025 Q3	$9.35M	Sell	170,108 -79,392	-32%	-$3.27M	0.15%	131
2025 Q2	$8.24M	Sell	249,500 -133,196	-35%	-$4.63M	0.14%	131
2025 Q1	$15.4M	Buy	382,696 +128,548	+51%	+$5.91M	0.31%	98
2024 Q4	$12M	Hold	254,148	–	–	0.22%	127
2024 Q3	$13.4M	Hold	254,148	–	–	0.23%	106
2024 Q2	$13.8M	Hold	254,148	–	–	0.24%	111
2024 Q1	$17.8M	Sell	254,148 -301,852	-54%	-$23.3M	0.28%	99
2023 Q4	$46.4M	Hold	556,000	–	–	0.76%	45
2023 Q3	$16.4M	Hold	556,000	–	–	0.29%	95
2023 Q2	$18.1M	Hold	556,000	–	–	0.31%	89
2023 Q1	$19.6M	Hold	556,000	–	–	0.36%	86
2022 Q4	$25.5M	Buy	+556,000	New	+$23.9M	0.5%	64

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eventide Asset Management's CYTK Position: Q2 2026 in Review

Eventide Asset Management increased its Cytokinetics (CYTK) stake by 18% in Q2 2026, buying an estimated $6.12M and bringing the position to 564,398 shares worth $48.1M. The position accounts for 0.64% of the portfolio, ranked #53.

Eventide Asset Management first reported a position in CYTK in Q4 2022 and has held it in 15 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Eventide Asset Management held 564,398 shares of Cytokinetics worth $48.1M as of Q2 2026.
Eventide Asset Management bought 85,300 Cytokinetics shares in Q2 2026, an estimated $6.12M.
Cytokinetics made up 0.64% of Eventide Asset Management's portfolio in Q2 2026, its #53 holding.
Eventide Asset Management first reported a position in Cytokinetics in Q4 2022 and has held it in 15 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.